Jiangxi Rimag Group (HKG:2522) expects to incur a net loss of between 55 million yuan and 60 million yuan in 2024, swinging from the year-ago profit of 36.6 million yuan, according to a Hong Kong Stock Exchange filing on Tuesday.
The medical imaging solution services company attributed the forecasted loss to the macroeconomic environment and a slowdown in demand, as well as the incurrence of certain expenses.
The actual financial results are set to be published on or before March 31, the filing said.
The company's shares closed less than 4% higher.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.